BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Semzuvolimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Semzuvolimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04985890-1019@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semzuvolimab: Phase 2 readout est. (NCT04985890)
DESCRIPTION:Semzuvolimab\, phase 2\, HIV.\nStudy: A Proof of Concept Study 
 to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Vira
 l Reservoir\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/semzuvolimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04985890
URL:https://assetmemo.bio/drug/semzuvolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
